Acalabrutinib (ACP-196)

Catalog No.S8116

For research use only.

Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.

Acalabrutinib (ACP-196) Chemical Structure

CAS No. 1420477-60-6

Selleck's Acalabrutinib (ACP-196) has been cited by 32 publications

Purity & Quality Control

Choose Selective BTK Inhibitors

Biological Activity

Description Acalabrutinib (ACP-196) is a selective second-generation Bruton's tyrosine kinase (BTK) inhibitor with an IC50 of 3 nM, which prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. ACP-196 has improved target specificity over ibrutinib with 323-, 94-, 19- and 9-fold selectivity over the other TEC kinase family members (ITK, TXK, BMX, and TEC, respectively) and no activity against EGFR.
Targets
BTK [1]
(in a human whole-blood CD69 B cell activation assay)
3nM
In vitro

In the in vitro signaling assay on primary human CLL cells, acalabrutinib inhibits tyrosine phosphorylation of downstream targets of ERK, IKB, and AKT. Acalabrutinib demonstrates higher selectivity for BTK with IC50 determinations on nine kinases with a cysteine residue in the same position as BTK. Importantly, unlike ibrutinib, acalabrutinib does not inhibit EGFR, ITK, or TEC. acalabrutinib has no effect on EGFR phosphorylation on tyrosine residues Y1068 and Y1173. Compared with ibrutinib, acalabrutinib has much higher IC50(>1000 nM) or virtually no inhibition on kinase activities of ITK, EGFR, ERBB2, ERBB4, JAK3, BLK, FGR, FYN, HCK, LCK, LYN, SRC, and YES1[1].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CLL cells M2L6[mFxd3C2b4Ppd{Bie3OjeR?= Mnj5NUDPxE1ib4KgN{DPxE1? MV:yOEwhPDhiYX7kJFczKGh? NHXISnZqdmO{ZXHz[ZMhcW5iYYDvdJRwe2m|IILheIV{KGmwIIDybY1ienliQ1zMJINmdGy|IHH0JFI1NCB2ODygZY5lKDd{IHjveZJ{KG:oIITy[YF1dWWwdB?= NV71SlF5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwN|Q6ODdpPkK4NFM1QTB5PD;hQi=>
B cells NEHUNHZHfW6ldHnvckBie3OjeR?= MVuxJIhz NFzz[GpKdmirYnn0bY9vKG:oIFLUT{BqdiCqdX3hckB4cG:uZTDicI9w\C2mZYLpeoVlKEOGMUmrJGIh[2WubIOgZZN{\XO|ZXSgZZMhe3WycILld5Nqd25ib3[gZY51cS2LZ12gd5RqdXWuYYTl[E1ETDZ7IHX4dJJme3Orb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKG[xbHzve4VlKGK7IFnnUUB{fGmvdXzheIlwdiCob4KgNVghcHK|IHL5JGZCS1NiYX7hcJl{cXNuIFnDOVAhRSByLkG5PEDPxE1w NEjHfow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUS1O|k5Oid-Mkm0OVc6QDJ:L3G+
Assay
Methods Test Index PMID
Western blot pBTK / BTK / pAKT / AKT / pERK / ERK / pS6 / S6 28034907
In vivo oral administration of ACP-196 in mice results in dose-dependent inhibition of anti-IgM-induced CD86 expression in CD19+ splenocytes with an ED50 of 0.34 mg/kg compared to 0.91 mg/kg for ibrutinib. A similar model is used to compare the duration of Btk inhibition after a single oral dose of 25 mg/kg. ACP-196 inhibits CD86 expression >90% at 3h postdose[3].

Protocol (from reference)

Cell Research:

[1]

  • Cell lines: primary human CLL cells,T cells, NK cells, and epithelial cells
  • Concentrations: --
  • Incubation Time: --
  • Method:

    --

Animal Research:

[2]

  • Animal Models: canine model of B cell NHL
  • Dosages: 2.5, 5, 10 mg/kg.
  • Administration: orally administered 

Solubility (25°C)

In vitro

DMSO 93 mg/mL
(199.78 mM)
Ethanol 93 mg/mL
(199.78 mM)
Water Insoluble

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.

6mg/mL

Chemical Information

Molecular Weight 465.51
Formula

C26H23N7O2

CAS No. 1420477-60-6
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC#CC(=O)N1CCCC1C2=NC(=C3N2C=CN=C3N)C4=CC=C(C=C4)C(=O)NC5=CC=CC=N5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04660045 Not yet recruiting Drug: Acalabrutinib Chronic Lymphocytic Leukemia|CLL/SLL Weill Medical College of Cornell University|AstraZeneca February 2022 Phase 2
NCT05038904 Recruiting Drug: Acalabrutinib Food Allergy|Food Allergy Peanut Johns Hopkins University|AstraZeneca December 16 2021 Phase 2
NCT04546620 Recruiting Drug: R-CHOP|Drug: R-CHOP + acalabrutinib Diffuse Large B Cell Lymphoma University Hospital Southampton NHS Foundation Trust|AstraZeneca October 19 2021 Phase 2
NCT04963946 Not yet recruiting Drug: Stop ACA|Drug: ACA Continuation Untreated Chronic Lymphocytic Leukemia French Innovative Leukemia Organisation September 15 2021 Phase 2
NCT04930536 Recruiting Drug: Acalabrutinib capsule Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma AstraZeneca July 14 2021 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Acalabrutinib (ACP-196) | Acalabrutinib (ACP-196) supplier | purchase Acalabrutinib (ACP-196) | Acalabrutinib (ACP-196) cost | Acalabrutinib (ACP-196) manufacturer | order Acalabrutinib (ACP-196) | Acalabrutinib (ACP-196) distributor